Monitoring Oxidative Stress in Acute Coronary Syndrome
Research type
Research Study
Full title
Development and application of a high throughput assay for monitoring oxidative stress in acute coronary syndrome
IRAS ID
189016
Contact name
Angela Doughty
Contact email
Sponsor organisation
NIHR Clinical Research Network: West Midlands
Duration of Study in the UK
3 years, 9 months, 11 days
Research summary
Coronary (heart) artery disease (CAD) is a major health burden in the UK, around 700,000 patients present annually with chest pain in England and Wales and approximately 350,000 of these cases are linked to emergency chest pain admissions. Coronary artery disease occurs when the blood vessels that supply the heart progressively become narrowed (atherosclerosis) and blocked. This results in oxygen failing to reach the heart muscle causing a heart attack.
The mortality rate associated with a heart attack is high, early detection is paramount so that correct treatment can be administered. The current ‘gold-standard’ for diagnosis involves measuring compounds which are released from the heart muscle into the blood following heart attack (cardiac markers). However, many cardiac markers are only detectible several hours, or even days, following a heart attack. During this period, the condition may worsen and further damage to the heart may lead to an unfavourable prognosis. Thus there is need to validate new robust markers that may be detected in a quicker timeframe.
A promising candidate for this is a compound known as allantoin. However, current methods of detection are unsustainable and the clinical utility for routine screening for cardiovascular disease is unknown. Moreover, the time-frame of detection leading up to and following a heart attack is poorly understood. Thus this project seeks to:
a) Develop and optimise a cost effective high throughput test to measure allantoin.
b) Monitor patient allantoin levels over a given timeframe leading to and following heart attack.
c) Validate the clinical utility of this test for cardiovascular disease patients against the current ‘gold-standard’.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
17/WM/0132
Date of REC Opinion
26 May 2017
REC opinion
Further Information Favourable Opinion